Assembly biosciences and arbutus biopharma initiate phase 2 clinical trial of triple combination therapy for the treatment of chronic hepatitis b virus

Trial will evaluate assembly's core inhibitor candidate, vebicorvir, with arbutus' rnai therapeutic candidate, ab-729, and standard-of-care nrti therapy
ABUS Ratings Summary
ABUS Quant Ranking